Standards message here
The Division's clinical faculty are board-certified Pediatric Hematologists/Oncologists. They conduct clinical and translational research in programs sponsored by the National Institute of Health (NIH) and the Maternal Child Health Bureau. Their expertise in the areas of hemophilia, autoimmune thrombocytopenia, thalassemia, sickle cell disease and the childhood leukemias and cancers are world renown and conduct clinical and translational research in NIH- and MCHB-sponsored programs. In addition, the Division's research scientists conduct basic research in the Children's Cancer & Blood Foundation laboratories in the fields of iron metabolism, immunology, hemophilia, cellular oncology and beta globin gene transfer.
The clinical program provides state-of-the-art comprehensive medical treatments for blood disorders such as anemias, neutropenias, thrombocytopenias, disorders of iron metabolism, coagulation and bleeding, as well as childhood leukemias and cancers such as lymphomas, Hodgkin's disease, Wilm's tumor, neuroblastoma, and osteogenic sarcoma. Psychosocial support for these children and their families is also provided with on-site social work and genetic counseling services. Nursing services, including that of a thalassemia and oncology nurse practitioner and infusion nurses, assist in the care and administration of medications, blood products, infusions and chemotherapy.
Dr. Patricia Giardina is the Director of the Comprehensive Thalassemia Center, the oldest and largest center of its kind in the United States. The Center provides comprehensive medical and psychosocial services, with thalassemia screening and genetic counseling, in conjunction with regular outpatient transfusion and iron chelation therapies. Outreach thalassemia screening and genetic counseling services are also conducted in satellite programs in lower Manhattan and Queens. She is the principal investigator of the NIH-sponsored New York Region Thalassemia Clinical Research Network. Dr. Giardina is currently conducting clinical research trials on potential oral iron chelators and the long-term efficacy of the first FDA approved oral iron chelator. Her basic research interests lie in curative therapies for Thalassemia and advancing the understanding of gene transfer.
Dr. Alexander Aledo directs our Pediatric Oncology Program, which diagnoses and treats infants, children, adolescents, and young adults with leukemias, lymphomas, sarcomas, and other childhood cancers. Dr. Aledo is also the Pediatric Hematology/Oncology consultant at New York Hospital Queens, which is part of the NewYork-Presbyterian Hospital Network. He is currently a member of the Leukemia Study Committee of the national collaborative Children's Oncology Group, which conducts clinical research trials for the treatment of high risk Acute Lymphoblastic Leukemia in children and adolescents.
Dr. James Bussel directs the Thrombocytopenia Program and is Principal Investigator in the New York Region Hemostasis and Transfusion Network, sponsored by the NIH. He has developed IV gamma globulin and Anti-D treatments for Immune (Idiopathic) Thrombocytopenia Purpura (ITP) patients and prepared national guidelines for the management of ITP. He is currently investigating the role of thrombopoietin treatment for refractory ITP patients.Dr. Catherine McGuinn directs the Hemophilia Center.
Chief: Sujit Sheth, MD
Alexander Aledo, MD
James B. Bussel, MD
Susanna Cunningham-Rundles, PhD
Patricia J. Giardina, MD
Nicole Kucine, MD
David C. Lyden, MD, PhD
Catherine McGuinn, MD
W. Beau Mitchell, MD
Stefano Rivella, PhD
Lisa G. Roth, MD